Suppr超能文献

我们应该通过静态风险评分还是动态风险评分来评估卒中风险?关注房颤患者卒中与出血风险的动态变化。

Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation.

机构信息

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.

Department of Internal Diseases, Diabetology and Nephrology, Silesian Medical University, Zabrze, Poland.

出版信息

J Cardiovasc Pharmacol. 2019 Dec;74(6):491-498. doi: 10.1097/FJC.0000000000000750.

Abstract

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and a major risk factor for stroke. The number of patients with AF is predicted to increase in the next few decades. AF has also negative impact on quality of life as well as it significantly increases the risk of cardiovascular disease and overall mortality. Because the stroke is a pivotal outcome of AF, its prevention with the use of anticoagulation therapy constitutes an important component of AF management. The decision on oral anticoagulants' prescription should be based on appropriate risk stratification to allow for comprehensive assessment of benefit/hazard ratio of stroke and bleeding along with patients' preference. Several risk scores for stroke and bleeding as well as for stroke and systemic embolism have been developed, mainly in patients on vitamin K antagonists. AF guidelines stress the need for repetitive evaluation of thromboembolic and bleeding risks to tailor optimal AF management. Indeed, risk is not a static "one off" process and it should be adjusted for dynamic nature of risk factors. However, most risk scores are calculated according to baseline characteristics of patients, but the older the patients get, the more comorbidities they acquire, which influences stroke risk significantly. Hence, the default management of every patient with AF should include a regular reassessment of stroke and bleeding risk factors.

摘要

心房颤动(AF)是最常见的心律失常,也是中风的主要危险因素。预计在未来几十年,AF 患者的数量将会增加。AF 还会对生活质量产生负面影响,同时显著增加心血管疾病和全因死亡率的风险。由于中风是 AF 的关键结局,因此使用抗凝治疗预防中风构成了 AF 管理的重要组成部分。口服抗凝剂处方的决定应基于适当的风险分层,以便对中风和出血的获益/风险比以及患者的偏好进行全面评估。已经开发了几种用于中风和出血以及中风和全身性栓塞的风险评分,主要是在使用维生素 K 拮抗剂的患者中。AF 指南强调需要重复评估血栓栓塞和出血风险,以制定最佳的 AF 管理方案。事实上,风险不是一个静态的“一次性”过程,它应该根据风险因素的动态性质进行调整。然而,大多数风险评分是根据患者的基线特征计算的,但患者年龄越大,获得的合并症就越多,这会显著影响中风风险。因此,每个 AF 患者的默认管理都应该包括定期重新评估中风和出血风险因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验